Anti-inflammatory Roles of Glucocorticoids Are Mediated by Foxp3+ Regulatory T Cells via a miR-342-Dependent Mechanism

Glucocorticoids (GC) are the mainstay treatment option for inflammatory conditions. Despite the broad usage of GC, the mechanisms by which GC exerts its effects remain elusive. Here, utilizing murine autoimmune and allergic inflammation models, we report that Foxp3+ regulatory T (Treg) cells are irreplaceable GC target cells in vivo. Dexamethasone (Dex) administered in the absence of Treg cells completely lost its ability to control inflammation, and the lack of glucocorticoid receptor in Treg cells alone resulted in the loss of therapeutic ability of Dex. Mechanistically, Dex induced miR-342-3p specifically in Treg cells and miR-342-3p directly targeted the mTORC2 component, Rictor. Altering miRNA-342-3p or Rictor expression in Treg cells dysregulated metabolic programming in Treg cells, controlling their regulatory functions in vivo. Our results uncover a previously unknown contribution of Treg cells during glucocorticoid-mediated treatment of inflammation and the underlying mechanisms operated via the Dex-miR-342-Rictor axis. [Display omitted] •Without Foxp3+ Treg cells, glucocorticoid loses its therapeutic effects•Glucocorticoid induces miR-342-3p expression specifically in Treg cells•miR-342-3p targets Rictor and regulates the metabolic programming in Treg cells•miR-342-3p and Rictor expression controls Treg cell function in vivo Glucocorticoids are the first line treatment option for acute and chronic inflammatory conditions, yet the underlying mechanisms remain largely elusive. Kim et al demonstrate that Foxp3+ regulatory T cells are key mediators of glucocorticoid-induced treatment by miR-342-dependent metabolic control in Treg cells.